Inhibitory activity
The degree to which a compound binds to a protein thought to cause a specific disease indication and inhibits the function of the protein. Usually expressed in terms of the concentration of the compound.
 Drug candidate compound design technology
Optimum Packing of Molecular Fragments (OPMF), a software module developed by Fujitsu that designs small molecule compounds that bind to the functional site of proteins that are believed to cause specific disease indications and inhibit the activity of the proteins.
A computational method developed by Fujitsu Laboratories for rapidly and accurately predicting the quantitative activity of a compound using multiple binding patterns.
 High-precision activity prediction technology
Software developed by Fujitsu Laboratories, comprised of MAPLECAFEE, a module that, based on molecular dynamics calculations, predicts the inhibitory activity of drug candidate compounds with a high level of precision that is equivalent to that of biochemical assays, and Force Field Formulator for Organic Molecules (FF-FOM), a module that generates highly detailed parameters for calculating the forces between atoms.
 Conformational analysis
A method of analyzing the relationship between a compound’s conformation (three-dimensional structure) and its potential energy.
Research Center for Advanced Science and Technology (RCAST) aims to contribute to the development of science and technology by expeditiously taking on new challenges arising from the advancement of science and coincident changes in society, and by exploring new areas of advanced science and technology for the benefit of humankind and society. Find out more at http://www.rcast.u-tokyo.ac.jp.
Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 140,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.1 trillion yen (US $39 billion) for the fiscal year ended March 31, 2018. For more information, please see www.fujitsu.com.
Kowa Company, Ltd. is a private multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa has been actively engaging in multidiscipline business including pharmaceuticals, textiles, machinery, and construction material fields. Its pharmaceutical division is focused on research and development for cardiovascular therapeutics, ophthalmology and anti-inflammatory agents. For more information, please see http://www.kowa.co.jp/eng.
Press ContactsPublic Relations Ikuko Murayama
Company:Research Center for Advanced Science and Technology, The University of Tokyo
Press ContactsPublic and Investor Relations Division
All company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.
Date: 13 June, 2018
City: Tokyo and Nagoya, Japan
Company: Research Center for Advanced Science and Technology, The University of Tokyo ,Fujitsu Limited ,Kowa Company, Ltd.
Share this page